EUCTR2007-004098-24-FR进行中（未招募）1 期
A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery - RADHER
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- FNCLCC
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1) Adult female patients (= 18 years old),
- •2) Histologically-confirmed diagnosis of invasive breast cancer, previously untreated (patients who have been treated for cancer of the controlateral breast cancer can be included if there is at least a 2 year time interval from last systemic treatment for breast cancer before randomization into this study),
- •3) Candidate for breast-conserving surgery; clinical stage: cT1-3, cN0-2
- •4) HER-2 positive primary tumor, defined as: IHC 3+, or IHC 2+ and FISH positive (centralized confirmation),
- •5) Clinical stage M0 (bone scan, chest X-ray, liver ultrasound required at screening to exclude metastatic disease),
- •6) WHO performance status = 1
- •7) Adequate bone marrow function (WBC = 3.5 x109/L; ANC = 1.5 x109/L; Platelets = 100 000x109/L; Hb =10 g/dL),
- •8) Adequate liver function (serum bilirubin = 1.5 ULN, serum transaminases activity = 2.5 ULN; alkaline phosphatase = 2.5 ULN),
- •9) Adequate renal function (creatinine = 1.5 mg/dL or creatine clearance = 60 mL/min),
- •10) Adequate cardiac (MUGA scan or echocardiography, FEV > 55%) and pulmonary functions,
- •11) Potentially reproductive patients must agree to use an effective contraceptive method while on treatment
- •12) Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and/or urine pregnancy test 48 hours prior to the administration of the first study treatment,
- •13) Patients must be affiliated to a Social Security System,
- •14) Patient information and written informed consent form signed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Patient not candidate for breast conserving surgery or patient candidate to neoadjuvant chemotherapy,
- •2) Patients with inflammatory breast cancer or patient with bilateral breast cancer,
- •3) Patients receiving concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy and radiotherapy,
- •4) Known hypersensitivity to everolimus or sirolimus, to trastuzumab or lactulose,
- •5) = gr 3 hypercholesterolemia/hypertriglyceridemia or = gr 2 hypercholesterolemia/hypertriglyceridemia with history of coronary artery disease (despite lipid-lowering treatment if given),
- •6) Patient with uncontrolled infection,
- •7) Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, cardiac disease, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within one year, chronic liver or renal disease, active GI tract ulceration, severly impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air),
- •8) Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itroconazole, Voriconazole, Ritonavir, Telithromycin) within the last 5 days prior to randomization,
- •9) Patients with a known history of HIV seropositivity,
- •10) Pregnant women, women who are likely to become pregnant or are breast-feeding,
- •11) Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial,
- •12) Patients who received any other investigational drugs within the 30 days prior to the screening visit,
- •13) Patients unwilling to participate to the biological investigations,
- •14) Individual deprived of liberty or placed under the authority of a tutor.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate THR-687 treatment for diabetic macular oedemaEUCTR2020-000362-42-DEOxurion NV303
进行中（未招募）
1 期
A study to evaluate THR-687 treatment for diabetic macular oedemaDiabetic macular oedema (DME)MedDRA version: 20.1Level: LLTClassification code 10057915Term: Diabetic macular oedemaSystem Organ Class: 100000004853MedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2020-000362-42-PTOxurion NV303
进行中（未招募）
1 期
A study to evaluate THR-149 treatment for diabetic macular oedemaDiabetic Macular Oedema (DME)MedDRA version: 20.1Level: LLTClassification code 10057915Term: Diabetic macular oedemaSystem Organ Class: 100000004853MedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2019-001506-17-FROxurion NV122
进行中（未招募）
1 期
A study to evaluate THR-149 treatment for diabetic macular oedemaEUCTR2019-001506-17-SKOxurion NV126
进行中（未招募）
1 期
A study to evaluate THR-687 treatment for diabetic macular oedemaEUCTR2020-000362-42-HUOxurion NV303